NCT06102057 - PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2028

Conditions

Stage III Non-small Cell Lung CancerLocally AdvancedUnresectable

Interventions

RADIATION

standard Radiotherapy

standard FDG-PET-based radiotherapy

DRUG

Chemotherapy

concurrent standard of care chemotherapy

DRUG

Immunotherapy

standard of care consolidation therapy with durvalumab (fixed dose of 1500 mg q4w) for up to 12 months or until progression of disease, unacceptable toxicity, patient´s wish, or investigator´s decision, whichever comes first.

RADIATION

Experimental Radiotherapy

FDG-PET-based small volume accelerated radiotherapy

Trial Locations (8)

8091

RECRUITING

Universitätsspital Zürich, Zurich

26121

RECRUITING

Pius-Hospital Oldenburg, Hematology and Oncology, Oldenburg

37075

RECRUITING

Universitätsmedizin Göttingen, Department for Radiotherapy and Radiooncology, Göttingen

41063

RECRUITING

Kliniken Maria Hilf GmbH Mönchengladbach, Mönchengladbach

66421

RECRUITING

Universität des Saarlandes, Klinik für Strahlentherapie und Radioonkologie, Homburg

70199

RECRUITING

Vinzenz Von Paul Kliniken gGmbH, Klinik für Strahlentherapie und Palliativmedizin, Stuttgart

79106

RECRUITING

Medical Center - University Of Freiburg, Department of Radiation Oncology, Freiburg im Breisgau

81377

RECRUITING

Klinikum der Universitaet Muenchen AöR, Department of Radiotherapy and Radiation Oncology, München